These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 27564097)

  • 21. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
    Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
    Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells.
    Valdez BC; Brammer JE; Li Y; Murray D; Teo EC; Liu Y; Hosing C; Nieto Y; Champlin RE; Andersson BS
    Leuk Res; 2016 Aug; 47():100-8. PubMed ID: 27294334
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells.
    Wang H; Chi CH; Zhang Y; Shi B; Jia R; Wang BJ
    Oncol Lett; 2019 Jul; 18(1):63-71. PubMed ID: 31289473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
    Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
    Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RhoB upregulation leads to either apoptosis or cytostasis through differential target selection.
    Marlow LA; Bok I; Smallridge RC; Copland JA
    Endocr Relat Cancer; 2015 Oct; 22(5):777-92. PubMed ID: 26206775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells.
    Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D
    Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines.
    Valdez BC; Nieto Y; Murray D; Li Y; Wang G; Champlin RE; Andersson BS
    Exp Hematol; 2012 Oct; 40(10):800-10. PubMed ID: 22687754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
    Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
    Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pan-histone deacetylase inhibitor panobinostat sensitizes gastric cancer cells to anthracyclines via induction of CITED2.
    Regel I; Merkl L; Friedrich T; Burgermeister E; Zimmermann W; Einwächter H; Herrmann K; Langer R; Röcken C; Hofheinz R; Schmid R; Ebert MP
    Gastroenterology; 2012 Jul; 143(1):99-109.e10. PubMed ID: 22465428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines.
    Sakajiri S; Kumagai T; Kawamata N; Saitoh T; Said JW; Koeffler HP
    Exp Hematol; 2005 Jan; 33(1):53-61. PubMed ID: 15661398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of class I histone deacetylase inhibitor romidepsin in combination regimens.
    Petrich A; Nabhan C
    Leuk Lymphoma; 2016 Aug; 57(8):1755-65. PubMed ID: 27118119
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Correlation of chemosensitivity measured by histoculture drug response assay to expression of multidrug resistance genes and proteins in gastric cancer].
    Yuan SQ; Zhou ZW; Liang YJ; Fu LW; Chen G; Keshari RP; Zhang LY
    Ai Zheng; 2009 Apr; 28(4):337-43. PubMed ID: 19622290
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
    Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
    J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ATP-binding cassette transporters in primary central nervous system lymphoma: decreased expression of MDR1 P-glycoprotein and breast cancer resistance protein in tumor capillary endothelial cells.
    Sakata S; Fujiwara M; Ohtsuka K; Kamma H; Nagane M; Sakamoto A; Fujioka Y
    Oncol Rep; 2011 Feb; 25(2):333-9. PubMed ID: 21165575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression.
    Wang Q; Tan R; Zhu X; Zhang Y; Tan Z; Su B; Li Y
    Oncotarget; 2016 Mar; 7(9):10064-72. PubMed ID: 26848526
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Different Schedule-Dependent Effects of Epigenetic Modifiers on Cytotoxicity by Anticancer Drugs in Colorectal Cancer Cells.
    Hosokawa M; Tanaka S; Ueda K; Iwakawa S
    Biol Pharm Bull; 2017 Dec; 40(12):2199-2204. PubMed ID: 28954936
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
    Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
    Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
    Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
    Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.